Cristin Rothfuss is EVP, General Counsel of Sarepta Therapeutics, Inc.. Currently has a direct ownership of 11,847 shares of SRPT, which is worth approximately $1.18 Million. The most recent transaction as insider was on Mar 07, 2025, when has been sold 1,478 shares (Common Stock) at a price of $103.7 per share, resulting in proceeds of $153,268. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 11.8K
14.26% 3M change
n/a 12M change
Total Value Held $1.18 Million

Cristin Rothfuss Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 07 2025
SELL
Payment of exercise price or tax liability
$153,268 $103.7 p/Share
1,478 Reduced 11.09%
11,847 Common Stock
Mar 04 2025
SELL
Payment of exercise price or tax liability
$59,182 $101.34 p/Share
584 Reduced 4.2%
13,325 Common Stock
Mar 03 2025
SELL
Payment of exercise price or tax liability
$40,574 $103.77 p/Share
391 Reduced 2.79%
13,621 Common Stock
Nov 26 2024
BUY
Grant, award, or other acquisition
-
2,000 Added 12.64%
13,817 Common Stock
CR

Cristin Rothfuss

EVP, General Counsel
Cambridge, MA

Track Institutional and Insider Activities on SRPT

Follow Sarepta Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SRPT shares.

Notify only if

Insider Trading

Get notified when an Sarepta Therapeutics, Inc. insider buys or sells SRPT shares.

Notify only if

News

Receive news related to Sarepta Therapeutics, Inc.

Track Activities on SRPT